Meconium aspiration syndrome (MAS) is a complex syndrome that ranges in severity from mild respiratory distress to severe respiratory failure, persistent pulmonary hypertension of the newborn and sometimes death. Understanding of the syndrome's complicated pathophysiology will help determine the appropriate treatment strategy, including the use of continuous positive airway pressure (CPAP), conventional mechanical ventilation (CMV) and other therapies. Approximately 30 to 50% of infants diagnosed with MAS will require CPAP or mechanical ventilation. The optimum modes of ventilation for MAS are not known. Very few studies have been conducted to determine 'best' ventilatory strategies. Despite the introduction, over the last two decades, of innovative ventilatory treatments for this disease (for example, surfactant, high-frequency ventilation, inhaled nitric oxide, extracorporeal membrane oxygenation), the majority of infants can be successfully managed with CPAP or mechanical ventilation alone.
Introduction
Approximately 30 to 50% of infants diagnosed with meconium aspiration syndrome (MAS) will require continuous positive airway pressure (CPAP) or mechanical ventilation. The optimum modes of ventilation for MAS are not known. Very few studies have been conducted to determine 'best' ventilatory strategies. Retrospective reviews of the application of conventional mechanical ventilation (CMV) to infants with this malady span three decades, during which time a host of adjunctive therapies have become available. 1, 2 Despite multiple therapies for this syndrome, there is a disturbingly high-mortality rate (4 to 19%) historically. However, in the most recent of these reviews, only 20% of 40 infants with MAS requiring positive pressure assistance needed 'innovative ventilatory support' (defined as the use of high-frequency ventilation (HFV), inhaled nitric oxide or surfactant) and no infants died or required extracorporeal membrane oxygenation. 2 It appears that when used optimally, conventional therapies are adequate to treat the majority of infants with this disease. Neonatal MAS challenges the practicing clinician to make the correct diagnosis, understand the changing and complex pathophysiology of the disease, and tailor the respiratory support to the specific alterations in pulmonary mechanics.
Making the diagnosis of MAS
Approximately 8 to 19% of all term deliveries occur through meconium-stained amniotic fluid (MSAF) and MAS develops in 5 to 33% of these infants. 3 Respiratory complications of MAS are often the consequence of hypoxia in utero with significant acidosis and depressed respirations at birth. There also appears to be a greater risk of developing MAS as well as all respiratory complications (that is, tachypnea, pneumonia, pulmonary air leaks) if the meconium is 'thick' as opposed to 'thin'. 4 However, a recent meta-analysis of the use of amnioinfusion showed no neonatal benefit when meconium was thinned through this process except in settings with limited peripartal surveillance. 5 Infants who are vigorous at birth have a very low risk of developing MAS. 6 Those who develop MAS are often greater than 41 weeks gestation and have clinical signs of postmaturity (decreased subcutaneous tissue, peeling skin, long nails and so on). The respiratory signs of MAS are similar to other neonatal respiratory diseases. These include tachypnea, retractions, grunting, nasal flaring and cyanosis. If the meconium has been present in utero for greater than 3 h, the infant may have meconium staining of the skin, nails and umbilical cord. The anterior-posterior diameter of the chest may be increased if there is significant air trapping.
The classic radiographic picture of MAS includes diffuse patchy infiltrates with areas of atelectasis mixed with areas of hyperinflation throughout the lung fields. However, initially the chest X-ray may not be very diagnostic, as it may take many hours for the chemical pneumonitis secondary to MAS to develop. Other findings on X-ray include possible air leaks and cardiomegaly, if significant perinatal asphyxia has resulted in cardiomyopathy.
Later in the course of the disease, the MAS picture may be complicated by the radiographic signs of surfactant deficiency (atelectasis, air bronchograms, decreased lung volume) as the surfactant system may be negatively impacted by the primary disease.
Despite the classic clinical and radiological appearance of MAS, it may be difficult in certain cases to distinguish MAS from other neonatal respiratory diseases. Table 1 lists the differential diagnosis. 7 It is important diagnostically and physiologically to determine if persistent pulmonary hypertension of the newborn (PPHN) is present with significant right-to-left shunting of blood through the foramen ovale and/or the ductus arteriosus resulting in exaggerated hypoxemia. PPHN may result secondary to MAS or may be present by itself ('primary PPHN') with concurrent MSAF but no true aspiration. As noted by Goetzman 8 in these cases of primary PPHN, 'when meconium is present, it is a fellow traveler and not the cause of the PHN (PPHN) and hypoxemia, contrary to what is often implied when MAS is used as the primary diagnosis.' Importantly, the treatment of the baby's respiratory disease will depend on the presence and severity of pulmonary hypertension.
Thus the diagnosis of MAS may be assumed when three criteria are met: (1) a history of meconium in the trachea; (2) clinical evidence of significant respiratory distress; and (3) X-ray evidence of aspiration pneumonia. 1 The association of transient tachypnea and MSAF without meconium in the airway or X-ray evidence of pneumonitis is often misdiagnosed as MAS and may lead to inappropriate treatment, including early positive pressure, which then may result in inadvertent pulmonary air leaks.
Pulmonary pathophysiology of MAS
Multiple mechanisms are involved in the pulmonary pathophysiology of MAS. Meconium has deleterious effects on the airways, injures the pulmonary parenchyma and alveoli, inhibits surfactant function and may cause hypoxic pulmonary vasoconstriction resulting in PPHN. The complex pulmonary effects of MAS are seen in Figure 1 . 9 Individual infants may manifest any one or more of these effects and the degree of respiratory distress may wax and wane according to the severity of the pathophysiology. Often there is a vicious cycle of air trapping, ventilation-perfusion mismatch, hypoxemia, right-to-left shunting, acidosis and increased pulmonary vascular resistance, which may be difficult to treat successfully with standard therapies.
Meconium may easily obstruct both the large and small airways in the newborn lung. When the obstruction is partial, a 'ball-valve' mechanism may lead to air trapping and air leaks (Figure 2) . 10 On inspiration the airway dilates allowing gas to enter, but during Figure 1 The complex pulmonary pathophysiology of meconium aspiration syndrome. From reference 9 with permission.
expiration the airway constricts around the obstruction, thus trapping air inside the lung. This may result in overexpansion of the lung, ventilation-perfusion mismatch, decreased compliance and possibly air leak. Complete obstruction of the airway by meconium may result in atelectasis and resultant hypoxemia and hypercapnia. Meconium also causes direct pulmonary parenchymal and alveolar injury resulting in a profound inflammatory response. The release and migration of inflammatory cells and mediators, such as cytokines and phospholipase A 2 , to the lung may cause direct pulmonary injury such as epithelial cell necrosis, cell death and apoptosis. 11, 12 These mediators may also result in constriction of pulmonary vessels, alteration and impairment of neutrophil function and cause capillary leakage and edema similar to respiratory distress syndrome. 9 Multiple investigations in both animals and humans have shown the deleterious effects of meconium on endogenous surfactant. [12] [13] [14] Meconium may inhibit surfactant production, displace surfactant from the alveolar surface and decrease its surface tension lowering function. Surfactant inhibition is concentration dependent and results from a variety of toxic biochemical effects of the meconium constituents. The influx of neutrophils into the airways subsequent to these toxic effects produces proteases, which further degrade surfactant proteins and frequently results in hemorrhagic edema of the lung.
Fox et al. 15 initially reported the association of pulmonary hypertension in association with perinatal aspiration syndromes. The majority of cases of significant PPHN are associated with MAS. The relationship of PPHN with MAS is complex and multifactorial. Vasoconstriction of pulmonary vessels may be associated with normal or increased muscularization of the vessel walls. 16 Prolonged in utero hypoxia may result in vascular remodeling secondary to hypertrophy of the medial musculature. Acute maladaptation secondary to intrapartum asphyxia with normal vessel anatomy is caused by the inhibition of endogenous pulmonary vasodilators and an inflammatory response resulting from MAS, which releases vasoconstrictive substances and causes platelet aggregation thus increasing pulmonary vascular resistance. Hypoxemia and acidosis also result in increased pulmonary artery pressure. Thus in both the acute and chronic hypoxic states, with normal or increased pulmonary vessel muscularization, the inflammatory response to MAS may trigger the vicious cycle of postnatal hypoxia, pulmonary vasoconstriction, right-to-left shunting and further hypoxia. In the presence of chronic vascular remodeling, the combination of MAS and PPHN is much more difficult to treat.
Altered pulmonary mechanics of MAS
In the theoretical classification of neonatal pulmonary disorders, MAS is considered an obstructive disease, although in reality the condition is both obstructive and atelectatic, and changes with time and treatment. Table 2 shows the physiologic differences between 'pure' atelectatic and obstructive lung disease. 17 MAS is characterized in this simplified chart as an obstructive disease with increased lung volume, decreased compliance, increased functional residual capacity and increased airway resistance and time constants. The pathophysiology of MAS discussed in the previous section alters the respiratory mechanics of the lung in four major ways as seen in Table 3 . Understanding the principles of normal ventilation and the alteration in respiratory mechanics secondary to MAS pathology is necessary to devise ventilation strategies to treat affected infants with CPAP and/or CMV.
Meconium in the pulmonary airways leads to increased airway resistance and prolonged time constants. The time constant is a measure of how quickly the lung can inflate or deflate, or how long it takes for alveolar and proximal airway pressures to equilibrate. The expiratory time constant (K t ) is directly related to both compliance (C L ) and airway resistance (Raw) by the equation: K t ¼ C L Â Raw. It takes three time constants to discharge 95% of the tidal volume of one breath. If the time constant is prolonged secondary to increased airway resistance (without a concomitant reduction in lung compliance), the patient is at risk a b Figure 2 Air trapping behind particulate matter (i.e. meconium) in an airway, which leads to alveolar overexpansion and rupture. Tidal gas passes the meconium on inspiration when the airway dilates (a), but does not exit on expiration when the airways constrict (b). From reference 10 with permission. for incomplete emptying of the previously inspired breath. This condition may be exaggerated when the patient is on assisted ventilation and there is insufficient ventilator time for exhalation because of an abnormally long time constant. The result of this 'inadvertent PEEP'will be gas trapping accompanied by an increase in lung volume, a build up of pressure in the alveoli and distal airways, and decreased compliance. 18 Significant air trapping may result in hyperinflation and flattening of the diaphragms on chest X-ray, increased anteriorposterior diameter of the chest and even cardiovascular effects such as decreased cardiac output, diminished blood pressure and signs of poor perfusion. Babies with increased functional residual capacity and high lung volumes have decreased compliance as seen in the flattened portion or section 'C' of the standard pressure-volume curve (Figure 3) . 19 Attempting to assist ventilation at the upper end of the compliance curve (that is, at high lung volumes) results in a further decrease in compliance and may lead to pulmonary air leaks.
As noted above, meconium has a direct injurious effect on the pulmonary airways, parenchyma and alveoli. This often results in capillary leak and edema. The additional injury of barovolutrauma from assisted ventilation through an endotracheal tube should be avoided if possible. Thus the use of oxygen by hood or cannula and nasal CPAP is advocated to avoid intubation and the bellows action of CMV. However, term and near-term infants may not tolerate nasal CPAP despite adequate sedation. Moreover, the use of a 'permissive hypercapnia' technique in these infants is problematic because of the sensitivity of the pulmonary vasculature to acidosis.
The deactivation of surfactant from MAS complicates this picture. It makes the use of PEEP mandatory during CMV despite the high functional residual capacity, increased time constant and air trapping that often occurs. Fox et al. 20 showed in a small number of infants (n ¼ 14) that moderate levels of PEEP (4 to 7 cm H 2 O) resulted in the greatest increase in oxygenation in babies ventilated for MAS (Figure 4) .
The addition of PPHN to the MAS pathophysiology further complicates the pulmonary mechanics and makes ventilatory strategies very difficult. Increased pulmonary vascular resistance may result from hypoxia, acidosis and reduced cardiac output. Ventilatory strategies must recognize these triggers. Allowing mild hyperoxia in these infants may reduce the periods of hypoxemia that occur with interventions or agitation. Pulmonary toilet must be done judiciously with careful attention to the pulse oximeter. Appropriate sedation and limiting interventions while nursing the infant in a dimly lit and quiet area of the neonatal intensive care unit are all helpful adjuncts to care. Although 'gentle ventilation' is recommended by some, 21 permissive hypercapnia and the resultant respiratory acidosis may worsen the pulmonary hypertension. At the other extreme, very aggressive assisted ventilation with hyperventilation in an attempt to improve oxygenation may contribute to overdistension of the lung, air leaks and decrease cardiac output, further aggravating the PPHN.
Conventional ventilation strategies
As there is little evidence from clinical trials on ventilator treatment of MAS, conventional management is primarily based on pulmonary pathophysiology. To avoid additional air trapping and possibly air leaks, many clinicians will treat initially with oxygen alone without positive pressure of any type. An inspired oxygen fraction (FiO 2 ) of up to 1.0 has been advocated in the past to treat hypoxemia. However, exposure to 100% oxygen for even brief periods of time in the newborn lamb increased the contractile response of small pulmonary arteries, presumably because of the production of reactive oxygen species. 22 Human and animal studies have shown significant biochemical and clinical negative effects after the use of 100% oxygen during resuscitation. Therefore, it may be prudent to avoid oxygen concentrations greater than 80% and switch to some form of positive pressure if concentrations higher than this are necessary. An oxyhood is preferred to nasal cannula as term and near-term infants may be less tolerant of a cannula, and the percentage of inspired oxygen can be greater in a hood. Sufficient oxygen should be given to maintain oxygen saturations 90 to 95%. The partial pressure of oxygen (PaO 2 ) target may be as high as 90 mm Hg as the risk of eye and lung toxicity is less in term infants, and the dangers of intermittent hypoxemia may result in the development or worsening of PPHN.
Although CPAP or CMV may be necessary to treat hypoxemia, hypercapnia and acidosis, there is no general agreement on blood gas parameters to initiate these therapies. Ambalavanan et al. The complicated pulmonary pathophysiology resulting from areas of atelectasis and areas of hyperinflation, in association with ventilation-perfusion mismatch and airway compromise, makes ventilator management of MAS one of neonatology's greatest challenges. The ventilator strategy used will depend on the stage and severity of the disease, especially the presence or absence of significant pulmonary hypertension. Clinicians vary in their desire to keep blood gas values in various ranges. Prior to the use of inhaled nitric oxide and HFV, some clinicians employed hyperventilation to achieve alkalosis by hypocapnia in an attempt to decrease pulmonary vascular resistance. 24 However, follow-up studies on infants managed with this strategy have shown an increased incidence of sensorineural hearing loss, pulmonary barotrauma and adverse neurologic outcomes. 25, 26 Thus hyperventilation has become a less-used strategy, as clinicians feel that the newer modalities such as HFV and/or inhaled nitric oxide are less dangerous than sustained hypocapnia. Contemporary management employs the acceptance of standard blood gas ranges or 'gentle ventilation,' a strategy in which higher PaCO 2 levels and lower PaO 2 levels are targeted in the belief that ventilator-induced lung injury will be reduced. 21 Other than the fear of intermittent hypoxemia worsening PPHN, there is probably little reason to keep babies hyperoxic. Moreover, catheterization data in older infants with pulmonary hypertension secondary to bronchopulmonary dysplasia suggest that oxygen tensions that exceed 70 to 80 mm Hg do little to decrease pulmonary artery pressure. 27 No trials have compared any of these strategies in the treatment of infants with MAS.
Infants with MAS without associated PPHN may be managed in a relatively standard fashion with slightly higher oxygen targets than used for premature infants with respiratory distress syndrome. The pH should be maintained above 7.3, PaCO 2 in the 40 to 50 mm Hg range and the PaO 2 targeted at 70 to 80 mm Hg. This may be achieved with a moderate peak inflating pressure preferably not exceeding 25 cm H 2 O, a relatively rapid ventilator rate (40 to 60 breaths per minute), a moderate PEEP (4 to 6 cm H 2 O) and an adequate expiratory time (0.5 to 0.7 s) to prevent air trapping. This strategy requires a relatively short inspiratory time of 0.3 to 0.4 s. If the diaphragms on chest X-ray are flat and gas trapping is suspected, the expiratory time should be increased to 0.7 to 0.9 s, PEEP decreased to 3 to 4 cm H 2 O and the rate decreased to allow at least a 0.25 inspiratory time. Borderline hypoxemia in this situation may be acceptable as increased ventilator settings may cause lung injury or the patient may be converted to HFV to improve oxygenation.
In infants whose MAS is complicated by significant PPHN, the ventilatory strategy is somewhat different. Intermittent hypoxemia can be mitigated by allowing the PaO 2 to be as high as 80 to 100 mm Hg without great concern for oxygen toxicity. As oxygen saturations have never been studied in this context and are surrogates for oxygen tensions, which do not correlate well when saturations are greater than 95%, monitoring by saturation alone is not recommended. Some clinicians also prefer to target mild hypocapnia (PaCO 2 range of 30 to 35 mm Hg), which results in mild alkalosis as a buffer to acidosis that may trigger a downward PPHN spiral. In both clinical situations of MAS with and without PPHN, a volume-recruitment strategy is preferred to recruit atelectatic areas of the lung and treat ventilation-perfusion mismatch. Such an approach resulted in improved oxygenation and less ventilator-induced lung injury in an experimental piglet model. 28 This strategy has to be tempered with the knowledge that such an approach may worsen air trapping in the face of mechanical airway obstruction.
All types of conventional methods of ventilation have been used in these cases. Most standard ventilators now allow the operator to choose among intermittent mandatory ventilation, patienttriggered ventilation, pressure support ventilation and/or volume controlled ventilation modes. None of these modalities have been compared with any other in a rigorous way, although each mode of ventilation has its supporters. As non-asphyxiated term infants may vigorously fight assisted ventilation, one approach has been to use a patient-triggered mode (synchronized intermittent mandatory ventilation or assist/control) in conjunction with adequate sedation. Muscle relaxation is rarely necessary and has significant drawbacks when this step is considered to achieve acceptable blood gases and avoid high ventilatory pressures and possible barotrauma, it may be time to move to alternative therapies (that is, inhaled nitric oxide, HFV). Careful attention must be paid to the environment in which these babies are nursed and ventilated. Although it seems appropriate to provide chest physiotherapy and pulmonary toilet, these interventions must be done with caution (or not at all) as they may trigger hypoxemia, agitation and an increase in pulmonary vascular resistance. Other nursing interventions must be considered in the same context with particular attention paid to minimize environmental stimuli such as light and noise.
Conclusions
MAS is a complex syndrome that ranges in severity from mild respiratory distress to severe respiratory failure, PPHN and sometimes death. Understanding of the syndrome's-complicated pathophysiology will help determine the appropriate treatment strategy, including the use of CPAP, CMV and other therapies. The use of echocardiography, pulmonary function studies and graphics will help guide the clinician in the choice of therapies. As shown by Bhutani et al. 2 at Pennsylvania Hospital over a period of 6 years, the use of a systems-based strategy for babies delivered through MSAF can minimize adverse outcomes. This review showed that conventional respiratory therapies such as oxygen, CPAP and CMV were adequate treatment for 80% of MAS-affected infants with no infant requiring extracorporeal membrane oxygenation or dying from the disease. In a time when the newest and most costly therapy seems to find a use in every patient, we can only admire and aspire to the benchmark that Dr Bhutani et al. have set.
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